-  Proceeds from strategic financing together with year-end cash resources expected to fund operations into mid-2025 including etripamil NDA submission and launch in PSVT -  The combination of etripamil's strong clinical results with this strategic financing lays the foundation to deliver a therapy

-  Both the NODE-303 and RAPID-extension studies are complete -  Following FDA feedback, Etripamil NDA is on-track for submission in the third quarter of 2023 -  Potential to be the first fast-acting, patient administered treatment to break PSVT episodes if approved MONTREAL and CHARLOTTE, N.C.

MONTREAL and CHARLOTTE, N.C. , Feb. 28, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will present at the